Background This study aimed to investigate the clinical characteristics, outcomes, and risk factors of patients with a rare but fatal manifestation of systemic lupus erythematosus (SLE), diffusive ...

Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies to various nuclear antigens and high serum cholesterol levels. 3-hydroxy ...

Background Previous US study presented a claims-based algorithm, consisted with comorbidities and medication information, to classify systemic lupus erythematosus (SLE) severity as mild, moderate or ...

Background To compare the prognosis of SLE patients who achieve clinically quiescent following treatment, with or without serologically active. Methods We categorized SLE patients from Lupus Clinic of ...

Background Systemic lupus erythematosus is a chronic-systemic autoimmune disease that may affect different organ and organ system. Pathogenesis of SLE is not well understood but high inflammatory ...

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with varied clinical manifestations and complex pathogenesis. SLE has a significant impact on morbidity, mortality and ...

Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Fernando Arizpe et al. Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough? Lupus Sci Med 2025;12:e001254. doi: ...

Background Systemic lupus erythematosus (SLE) often mimics the symptoms of other diseases, and the interval between symptom onset and diagnosis remains long in these patients. The aim of this study is ...

Background Around 963 A.D., Bishop Eraclius (Liège, Belgium) wrote an affidavit stating, ‘I … was nearly taken to death by the disease called Lupus.’ On the seventh night of praying at Saint Martin’s ...

Background Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib is a first-in-class, oral, selective, ...

Background Non-adherence to medical recommendations in childhood-onset systematic lupus erythematosus (cSLE) is estimated to be between 40%–50%. For patients with ...

Objective To investigate changes in peripheral B cells, B-cell subsets and biomarkers in NOBILITY. Methods In the randomized Phase II NOBILITY trial (NCT02550652), patients with lupus nephritis ...